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Abstract
Denture stomatitis (DS) is the most common oral pathology among denture wearers, affecting
over one-third of this group. DS is usually associated with C. albicans. However, unlike other oral
candidiasis, most DS patients have intact host immunity. The presence of a denture alone is
usually sufficient for DS. Saliva and its protein contents can theoretically predispose some denture
wearers to DS and others resistant toward DS. Here we proposed for the first time to define
salivary proteomic profiles of denture wearers with and without DS. SELDI-TOF/MS analysis
suggests that there is a proteomic differentiation among control, localized and generalized DS.
Based on initial SELDI-TOF/MS profiling, we further used reversed phase liquid chromatography,
MALDI-TOF/MS, and LC-MS/MS to characterize the salivary proteins associated with DS.
Nineteen proteins based on SELDI-TOF/MS profiling were found including cystatin-SN,
statherin, kininogen-1, desmocollin-2, carbonic anhydrase-6, peptidyl-prolyl cis–trans isomerase
A like peptides, cystatin C, and several immunoglobulin fragments. The proteomic content gives
evidence of the interaction between host tissue, saliva, and candida. Further examination in larger
populations of these proteins may help to gain a better understanding of DS pathological processes
and improve DS treatments.
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Denture stomatitis (DS) refers to an inflammatory reaction of mucosal tissue beneath the
denture. DS affects one-third to one-half of all denture wearers and, therefore, is the most
common oral pathological lesion in denture-wearing patients.1–5 The etiology of DS is
complex and there are controversial theories of how DS may be developed. There are
recognized etiological factors for DS including the presence of a denture, candidal organism
(in denture, saliva, or mucosal tissues), traumatic factors (often related to ill-fitting
dentures), inflammatory/immune response of the host, and oral environment (e.g. saliva,
other micro-organisms, etc.).1,6,7 DS clinical pathology was described by Newton in 1962
who classified DS into types I, II, and III depending on the extent of clinical pathology.8
DS only occurs in denture wearers and removal of the denture eliminates the condition.1–3
The roles of other factors in DS development are not clear. DS is often associated with
candidal infection; however unlike other forms of oral candidiasis, most DS patients have an
intact systemic immunity. In another difference, the presence of candida in mucosal tissues
does not correspond to the clinical severity of DS.2 The porosity of acrylic denture base
allows for biofilm formation and retention of microorganisms (such as candida) both on the
denture surface and within the denture.2,9 The presence of candida organisms in dentures is
directly associated with the extent of the mucosal tissue inflammation.7 The fitting of
dentures and irritation caused by denture movement often intensify DS.1–3,6
Clinically some denture patients present with recurrent or non-responsive DS while others
almost never develop DS suggesting that host factors play a role in DS development. One
unique feature of DS is the characteristic clinical inflammation of mucosal tissues
underneath the denture. Note also that DS is very common in maxillary dentures, regardless
of how well-fitted the denture is, while DS is much less abundant in mandibular
dentures.1,6,7 DS appears, therefore, to be patient-specific and a reaction to site-specific
inflammatory responses. Besides inflammatory host responses, the quantity of saliva and
salivary contents is important in all forms of oral candidiasis, including DS. Lack of saliva,
or xerostomia, is highly prevalent in-populations as a result of aging, medication side
effects, and other therapies, and further predisposes patients to DS.10,11
Certain salivary proteins have been shown to play a role as biomarkers and antifungal
proteins for oral candidiasis. For example, anti-p24 antibodies were increased in HIV+
patients with oral candidiasis.12 Increased salivary expression of Th1 and Th2 cytokines,
including IFN-gamma and IL-4, was shown to reduce candidal colonization in mice.13 Low
levels of salivary histatin-5, a protein shown to have anti-candidal activity in vitro, are
correlated to increased candidal infection in HIV+ patients.14–16 While there are several
studies investigating the role of salivary proteins in other forms of oral candidiasis, the role
of salivary proteins in DS that occurs in the healthy denture wearing population is not well-
understood.
In this study, we compared the proteomic profiling of edentulous patients with and without
DS using SELDI-TOF/MS to see if we could differentiate DS and non-DS denture wearing
subjects with salivary proteomics. Furthermore, we identified DS-associated salivary
proteins using MALDI-TOF/MS and LC-MS/MS based on SELDI-TOF/MS profiling. The
purpose of parallel platform utilization was to allow screening of the biomarkers from
samples in each individual subject without identification using the SELDI-TOF platform,
and at the same time, to allow identification of biomarkers using pooled samples from
control and DS II groups (the group with the majority of biomarkers with highest expression
compared to control and DS III). Using a combination of mass spectrometry- based
Bencharit et al. Page 2










proteomic analyses, we provide novel proteomic insight into the role of salivary proteins in
DS.
Results
Saliva samples were first analyzed on four different Protein Chip arrays as described earlier.
Several SELDI-TOF mass spectra of salivary protein profiles demonstrate differences in
profiles corresponding to different arrays for each subject. Examples of SELDI-TOF/MS
profiles are shown in Fig. 3 and 4. All identified peptide masses are summarized in Table 3.
Out of 61 identified masses, only 13 potential masses are down-regulated (Table S1, ESI†).
All peptide masses but one that are down-regulated are small peptides (m/z < 2300). Out of
48 up-regulated masses, 11 are more intense in DS II, for instance, the IMAC30 12 679 Da
mass and the CM10 13 264 Da mass (Fig. 3 and 4). The 13 264 Da mass has its highest
expression in the DS II samples. The IMAC30 10 621 Da and 12 679 Da masses are up-
regulated in both DS groups. Similarly, the Q10 3822 Da mass shows up-regulation in the
DS samples, in particular DS II. This 3822 Da mass was later identified (see below). The
data analysis reveals a set of peptide masses with lower expression levels in the DS samples.
It is possible that an elevated proteolytic activity under DS conditions may contribute to
smaller peptide masses. The CM10 35 125 Da mass is most dramatically reduced in the DS
II samples (Table 3). The Q10 12 954 Da mass shows a trend for lower expression,
especially in the DS III samples. Finally, the same mass at 2260 Da was detected on three
Protein Chip arrays; CM10, IMAC30 and Q10 arrays. SELDI-TOF/MS demonstrates
several protein/peptide expression unique to the healthy non-DS control, DS II, and DS III
subjects. When compared to all three groups, DS II demonstrates the most dramatic changes
of the masses (Table 3, Fig. 3 and 4). Fourteen masses have the highest relative expression
in DS II. We used ROC/AUC analyses (Table 3) to demonstrate the expression change for
each mass. Down-regulated masses have ROC close to 0, while up-regulated ones have
ROC close to 1. ROC ranges from 0.175 (~1436 Da mass) to 0.933 (~13 297 and 33 247 Da
masses).
Based on SELDI-TOF/MS profiling we further used LC-MS/MS to examine each mass
corresponding to SELDI peptide masses. The identities of 19 peptide masses were
elucidated (Tables S1 and S4, ESI†). We identified four secreted proteins from salivary
glands: statherin (STAT), cystatin-SN (CYTN), carbonic anhydrase 6 (CAH6), and peptidyl-
prolyl cis–trans isomerase A (PPIA) like peptides; a plasma/tissue protein: kininogen-1
(KNG-1); an epithelial protein: desmocollin-2 (DSC2); and several IgG variable region
immunoglobulin fragments. Except for one biomarker, KNG-1, which was eluted out from
the ProteinChip array, all of the biomarkers were identified based on approximate m/z
values from SELDI-TOF. We compared the level of each identified peptide mass between
the DS and control groups. Note that all of the identified peptide masses are up-regulated in
DS and most of them have the highest relative expression level in DS II. The level of
expression for each peptide (Tables 3 and 4, Table S1, ESI†) is described below. We,
therefore, chose pooled control samples and DS II samples for LC-MS/MS analysis.
The level of STAT (m/z = 3822.4) was increased over threefold in patients with DS
compared to controls. Similarly, the level of expression of CYTN (m/z = 7146.5) was
significantly increased in DS patients. The expression of KNG-1 (m/z = 5227) was increased
over two-fold in patients with DS compared to controls. The salivary level of DSC2 (m/z =
12608.4) was four to sixfold higher in the DS patients. PPIAs (m/z = 13267.3) were
increased over two-fold in DS subjects. Using mucosal transcriptome analysis we found that
PPIA gene expression was 1- to 5-fold higher in DS-affected mucosa compared to the
†Electronic supplementary information (ESI) available: See DOI: 10.1039/c2mb25283j
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unaffected tissues in the same DS patient (Table S2, ESI†). CYTC (m/z= 13274.1) level was
elevated in DS patients. Multiple proteins were identified as candidate immunoglobulin (Ig)
variable region fragments. All these Ig fragments were highly elevated in DS, especially in
the DS type II cases which reflects acute localized DS. They are also elevated (however to a
lesser degree than type II) in DS III, which presents with more chronic inflammation and
exists as a more generalized form of DS. This tentative identification was based on a
significant number of high scoring protein hits from the marker-containing fractions for Ig
variable regions.
Discussion
To elucidate the role of salivary proteins in DS development, we examined a salivary
proteomic analysis of DS. We selected edentulous patients wearing a maxillary denture with
DS compared to edentulous control subjects without DS. Our selection criteria used were
aimed to eliminate subjects that may be prone to oral candidiasis as a result of other host
factors, for example medication, cancer therapy, immunocompromised conditions, etc.17,18
Non-edentulous (dentate) subjects may have DS if they wear a partial denture. However, the
presence of teeth can change the dynamic of biomarkers. Several proteins from circulation
travel to the oral cavity through the periodontium around the teeth. The expression of serum
and inflammatory proteins from the periodontium is dependent on the periodontal health and
number of remaining teeth. Moreover, dentate patients with DS often present with
periodontal disease or dental caries. This will confound the results. Therefore, we elected to
not include dentate patients. While the cross-sectional nature of the study limits our
interpretation to a hypothesis-generating study, identified proteins seem to represent a
complex etiological feature of DS. In this study, we limited recruitment to healthy patients
in order to represent the elderly edentulous denture-wearing population with intact immune
systems.17,18
SELDI-TOF/MS analyses provide an unbiased proteomic profile for subject.19–22 It was
important to note here that this proteomic profiling corresponds well with clinical and
histological diagnosis of DS. More importantly, each protein is differentially expressed
among the non-DS, DS II and DS III individuals. DS development is poorly understood.
However, our SELDI-TOF/MS analysis suggests that the DS II group seems to have a more
robust host response in saliva. This agrees with the clinical feature of DS II that is localized
and acute in nature. On the other hand, the SELDI-TOF/MS profiles suggest the less robust
but chronic inflammatory responses in the DS III compared to DS II and control groups.
It is important to note that several of the candidate SELDI markers were not identified
similar to previously suggested by other investigators.23–25 This is likely due to several
factors. First, protein concentration in the original sample may have been high enough for
detection, however, dilution and protein loss during separation may have resulted in the
protein or corresponding peptides being below the limit of detection for the MS system.
Second, the protein biomarker may have been detected, however, native protein cleavage
processes may not be characterized or documented in the existing protein databases.
Therefore, the molecular weight (Mw) of the detected proteins in the database does not
match the Mw determined by SELDI analysis. Third, differences in system ionization and
instruments between the SELDI, MALDI and ESI systems may have resulted in detection of
the protein in one instrument, but not across all instruments. Fourth, poor LC/MS/MS
fragmentation and database annotation can result in collected LC/MS/MS data that do not
match database entries. And finally, modified proteins are frequently identified with low
probabilities or mis-identified due to limitations of the database search software. The
proteins identified using the methodology in this study are candidate protein matched to the
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original SELDI Mw signal. The differential expression of these candidate protein biomarkers
will need further assessment and validation in the future.
While SELDI-TOF/MS provides an overall picture of salivary proteomes, it does not give
protein identities. We therefore further used pooled saliva samples from control and DS II to
define the identity of each mass based on the initial SELDI-TOF/MS profiles. We were
surprised to observe that identified masses associated with DS in our study are different
from those previously identified in other forms of oral candidiasis. It was suspected that the
differences may be a result of different etiological factors, especially in regards to the
subjects systemic immunity. In summary, we identified three groups of DS-associated
masses based on their origins, including salivary gland, mucosal/epithelial, and immune
system origins.
Four salivary gland secreted proteins, including STAT, CYTN, CAH6, and PPIA, were
identified. We propose that these proteins may enhance DS through their interactions with
candida organism. The higher expression of STAT and CYTN in DS patients suggests the
role of salivary proteins in biofilm formation which is important in candidal colonization in
dentures.9 Salivary STAT and CYTN are both associated with Sjögren syndrome.26–28 It has
been shown that STAT and CYTN function together in biofilm formation and mineralization
in dentate patients.29–31 The salivary level of CYTN was increased in situation of a bleeding
oral cavity.32 In addition, it was shown that salivary CYTN inhibits lysosomal protease
activity of cathepsins.33 It is therefore plausible that these proteins may facilitate candidal
adherence and growth in dentures. CAH6 is an interesting salivary protein that was found to
be associated with several diseases including diabetes, periodontitis, dental caries, breast
cancer, and Sjögren syndrome.28,34–38 CAH6 catalyzes the reversible reaction H2CO3 =
CO2 + H2O39 and, therefore, regulates salivary pH. This controlled pH environment may
facilitate candidal growth in saliva. Note that instances of depleted CAH6 have been linked
to higher risks of dental caries and periodontitis, an outcome which may be a result of
favoring bacterial growth (not fungal growth). Note also that CAH6 is one of the most
common masses in saliva associated with oral and systemic disease.37–38,40–42 PPIAs were
shown to play an important role in the infection of HIV to host cells.43,44 The role of PPIA
peptides in candidal infection has yet to be understood. Three mucosal/epithelial originated
proteins, including KNG-1, DSC-2, and CYTC, were up-regulated in DS patients, providing
evidence of tissue damage resulting from DS. KNG-1 is a vasodilator.45 It is likely that
KNG-1 expression is a result of inflammation in the mucosal tissue. Similarly, DSC-2
demonstrates the signs of epithelial disruption.46 CYTC was thought to be associated with
dry mouth, gingivitis and periodontitis.36,47,48
It is important to note here that the majority of identified DS-associated proteins in our study
are immunoglobulin (Ig) fragments (11 out of 18 proteins). Again these masses express at
the highest level in the DS II group. These Igs can be a contribution of the salivary glands,
mucosal tissues, or systemic host immune systems. Increased Igs associated with DS are
similar to other conditions including breast cancer,35 dental caries,30,40 periodontal
disease,37 and Sjögren syndrome.26–28 While it is unlikely that Igs would be derived from
major salivary glands or systemic circulation in DS cases, it is possible that the inflamed
palatal salivary glands and palatal mucosa may be the major source of Igs.49–56 It is
important in the future to examine microbial-based immunoglobulin destruction-specific
cleavage of Ig protease. The large presence of Igs clearly demonstrates an important role for
the B cell-mediated immune response in DS that is often neglected, as it was previously
suggested that T cells and macrophages mediate immune response in DS.2,57,58 In addition,
traditional DS treatments focus only on eliminating candidal organisms and physical trauma.
In DS patients that are not responsive to these treatments, anti-inflammatory medications
may positively enhance other DS treatments.
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In conclusion, our proteomic analyses suggest that salivary proteomic profiling has a
potential in differentiating non-DS and DS subjects and therefore studying the salivary
proteins based on these profiles may provide insight into DS development. The majority of
DS-associated proteins are up-regulated in the DS group, especially DS II. Salivary proteins
originating from salivary glands may predispose patients to DS through enhancing candidal
survival or biofilm formation. Mucosal/epithelial originated proteins may be a result of
tissue damage resulting from the DS condition. Igs, the major group of proteins identified,
suggest the role of B cell mediated immunity, especially in DS II. Based on this
investigation, we concluded that salivary proteomics may be an important research tool for
studying DS in a prospective manner in the future.
Experimental procedures
Subjects and samples
Ten denture patients diagnosed with DS, using type II (DS II) and III (DS III) Newton
classifications (localized and generalized DS),8 and nine control denture patients without DS
were recruited (Fig. 1). All subjects wore a maxillary complete denture and were carefully
selected to minimize confounders (Table 1) as part of the larger cohort.17 The study protocol
was approved by the University of North Carolina Office of Human Research Ethics (IRB
No. 07-2014). All subjects consented using a written consent form. The clinical diagnosis of
DS was complemented by histological assessments (biopsy and swabs of the lesion), and by
culture (tissue, denture, and saliva). Similar to our previous saliva sample protocol,17,18
subjects were asked to refrain from drinking, eating, and practicing any oral hygiene habits 2
hours before sample collection. Prior to collection, subjects will be asked to rinse the mouth
with distilled water. This same protocol was used throughout our entire study to standardize
the protein biomarkers and to reduce contamination from food, tissue debris and blood. All
saliva samples will be collected before lunch time between 9 am and 12 pm to standardize
the collection and, more importantly, to minimize the circadian effect. Approximately 4 ml
of unstimulated whole saliva sample was collected in a 15 ml Falcon tube. The tube was
then centrifuged to remove food and tissue debris. The supernatant will be placed into
aliquots of 250 μl. All aliquots will be immediately frozen in liquid nitrogen to avoid
enzymatic and bacterial degradation of the protein content. The subject population includes
a control (edentulous patients wearing complete dentures with no DS) group (n=9), and a DS
group (n = 10); the DS II (n = 6) and the DS III (n = 4) (Table 2). The samples were kept in
−80 °C until all samples were transferred to the mass spectrometry facility. Mass
spectrometry analyses were completed for all samples simultaneously. The operators were
blinded of the group assignment until the data analysis stage. Fig. 2 shows the flowchart of
the mass spectrometry analyses.
Mass spectrometry proteomic analysis
Materials, reagents, and denaturation protocol—Materials for SELDI-TOF/MS
analysis included Denaturant (9 M urea, 2% CHAPS), Bio-Rad ProteinChip CM10 arrays,
Bio-Rad ProteinChip H50 arrays, Bio-Rad ProteinChip IMAC30 arrays, Bio-Rad
ProteinChip Q10 arrays, and Bio-Rad SPA matrix. Specific reagents that were used included
CM10 low stringency buffer: 0.1 M Na-acetate, pH 4.0; H50 binding buffer: 10%
acetonitrile, 0.1% TFA; IMAC30 binding buffer: 0.1 M sodium phosphate, 0.5 M NaCl, pH
7.0, and Q10 binding buffer: 50 mM Tris–Cl, pH 9.0. Each sample was denatured using the
following protocol. Saliva samples (40 μl) were denatured by addition of 60 μl urea/CHAPS
denaturant solution and incubated on ice for 30 minutes. A pooled reference sample
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(consisting of 10 μl aliquots of each individual denatured saliva sample) was used to
optimize the volume utilized in the SELDI protocol.
Instrument setting and protocol—Each of the saliva fractions was profiled on four
ProteinChip array types: CM10, H50, IMAC30 and Q10. The ProteinChip arrays were
equilibrated by two 5 minutes washes with 100 μl of the appropriate binding buffers listed
above. A total of 95 μl binding buffer was added to each ProteinChip array, followed by 5
μl of the denatured saliva. The samples were shaken for 1 hour using a MicroMix shaker.
The samples were removed and the arrays were washed with 3 × 150 μl aliquots of binding
buffer (5 minutes per wash step). The arrays were washed twice with 200 μl water (1 minute
per wash) to remove excess salts. The arrays were allowed to air dry. Finally, 2 × 1 μl
aliquots of SPA matrix (50% saturation, prepared in 50% acetonitrile, 0.5% TFA) were
added to each spot. The arrays were inserted into a ProteinChip (Enterprise) TOF-MS.
Quality control features were included as follows. Each sample was profiled in duplicate. In
addition, the pooled denatured saliva was profiled in hextuplicate on each array type to
assess reproducibility and performance. All samples were subjected to Protein Chip and
SELDI-TOF/MS at the same time. The operator was blinded of sample group assignment.
Data acquisition and analysis—The Bio-Rad SELDI ProteinChip reader (Enterprise
version) was used to collect spectra. Using the pooled reference samples, optimal laser
settings of 1800 nJ for low mass (2–20 K) and 3800 nJ for high mass (10–200 K) spectra
were determined. Both sets of spectra were obtained from each spot. SELDI ProteinChip
Data Manager software was utilized. Spectra underwent proper baseline fit and subtraction.
Spectra profiled on a specific chip type and using identical laser settings, were normalized
relative to the total ion current across the spectra. Mass calibration was performed using All-
in-1 peptide and All-in-1 protein standards. Univariate analysis was carried out to indicate
specific m/z markers, which demonstrate differential expression across the various groups.
Peak clusters were assigned using the Expression Difference Mapping (EDM) feature of
ProteinChip Data Manager software.
Each cluster was constructed by detecting individual peaks with signal/noise values >5 and
which were present in greater than 20% of the spectra. The peak intensities detected in the
duplicate spectra obtained for each sample were averaged, providing the 21 independent
samples for statistical (Mann– Whitney) analysis. The Wilcoxon rank sum test or Kruskal–
Wallis analysis of variance (ANOVA) was performed for numeric variables. Pearson’s chi-
square test is used for categorical variables. For each mass, the discriminatory power was
further described via receiver operating characteristic (ROC) area under the curve (AUC)
analysis using SPSS Version 12.0 software (SPSS Inc., Chicago, IL).18 Initially, the control,
DS II and DS III spectra were analyzed as 3 separate groups. These data are presented in the
“Split” markers listed in the Combined Markers spreadsheet. In addition, comparison of the
control spectra vs. the combined DS (II and III) groups was carried out. These markers are
listed in the “Merged” marker list on the same spreadsheet.
Saliva sample 2-dimensional LC separation—A pooled patient aliquot was created
for each of the healthy and somatitis II sample subsets and used for protein separation and
marker identification. Each pooled aliquot was separated on an Agilent 3100 OFFGEL
Fractionator. A total of 4 lanes were prepared for each sample; 500 μL of sample was
loaded into each lane. A standard protein QC mix was also prepared for each plate utilized.
Samples were separated using a 64 kV h−1 separation according to the manufacturer’s
instructions. A total of 24 fractions were collected after separation. These fractions were
pooled, to generate 6 fractions for each of the healthy and DS II samples.
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Each of the OFFGEL saliva fractions and a single selected QC OFFGEL fraction were then
separated by LC. Solvent A was 95/5/0.1 H2O/ACN/FA, solvent B was 5/95/0.85 H2O/
ACN/FA. Each OFFGEL fraction was pre-loaded onto a PROTO 300 C4 5 μm particle size
(20 × 2.1 mm) trap column offline using a syringe pump, and the bound material was
washed with at least 1 ml 100% A. The trap column was then placed in-line in the LC
system and the proteins were separated on a PROTO 300 C4 5 μm particle size (150 × 2.1
mm) column using an Agilent 2100 LC system coupled to an Akta fraction collector. A
linear LC gradient 0.2 μL min−1 of 0–10 min at 5% B, 12 min to 10% B, 50 min to 80% B,
55 min to 100% B, hold for 10 min at 100% B was used for protein separation. Fractions
were collected each minute throughout the gradient.
Collected fractions were concentrated to dryness in a vacuum centrifuge and the proteins
were re-solubilized in 10 μL 75/25/0.1 ACN/H2O/FA. Concentrated samples were layered
1 : 1 with a MALDI matrix (20 mg ml−1 sinapinic acid in 75/25/0.1 ACN/H2O/FA) and
deposited on a MALDI target plate. Samples were analyzed on an Applied Biosystems 4800
MALDI TOF/TOF mass spectrometer. Two spectra were acquired for each sample, from m/
z 800–20 000 and 2000–100 000. Mass spectra were screened using an automated in-house
program for masses that corresponded to the candidate markers.
Protein identification—LC fractions containing the m/z markers of interest were trypsin
digested and analyzed by LC/MS/MS for protein identification. Fractions were concentrated
to dryness in a vacuum centrifuge and reconstituted in 50 μL 50 mM ammonium
bicarbonate. Fractions for digestion were reduced and alkylated, and digested overnight with
trypsin. Fractions were concentrated prior to LC/MS using a vacuum centrifuge. Processed
fractions were analyzed by LC/MS/MS for protein ID. A total of 10 μL of each processed
sample was injected and separated on a Waters nanoAQCUITY UPLC coupled to an
Applied Biosystems 4000 QTRAP system. A Waters nanoACQUITY BEH 1.7 μm particle
size (100 μm × 10 cm) column was used for the protein separation. Mass spectra results
were submitted to Mascot (Matrix Sciences) for a database search against the SwissProt
(March 2009) and NCBI (December 2009) Human database. Search results were compared
against the intact marker Mw identified in the sample fractions. Candidate protein
identifications were highlighted that matched or could account for the intact Mw detected by
SELDI and MALDI MS analysis.
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Clinical photographs of (A) a control subject, (B) Newton classification II stomatitis, and
(C) Newton classification III stomatitis.
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Flow diagram showing (top) SELDI-TOF/MS analysis screening for masses associated with
DS in denture patients by mass (m/z), and (bottom) combination of liquid chromatography,
MALDI-TOF/MS and LC-MS/MS in the identification process for masses correlated with
m/z information from SELDI-TOF/MS.
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Examples of SELDI-TOF profilings for healthy control, DS II and III samples; (A)
mass~2260 Da (Q10 array); (B) mass~2260 Da (Q10 array); and (C) mass ~12 670 Da
(IMAC30 array).
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Differential fold expression of 4masses identified by SELDI-TOF/MS in four different
Protein Chip arrays; (A) H50 array with 5283 kDa mass, (B) Q10 array with 5227 kDa
mass, (C) IMAC30 array with 12 679 kDa mass, and (D) CM10 array with 13 274 kDa
mass.
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Table 1
Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1 At least 45 years of age
2 Male or females without menses for 12
consecutive months or who have had a
complete hysterectomy
3 Wear complete maxillary denture
(overdentures, implant or tooth retained
dentures acceptable) without daily use of
denture adhesives
4 Must have read, understood and signed an
informed consent form
5 Must understand and be willing to comply
with all study procedures and restrictions
6 Must be in good general health; diabetics
included
7 Must have Type II or Type III DS for the
denture stomatitis group
8 Must have no signs of DS for the control
group
1 Less than 45 years of age
2 Have chronic disease with oral manifestations other than denture/
mucosal stomatitis
3 Have gross oral pathology
4 Have overt denture abrasion associated with symptoms
5 Participants with clinically significant organic diseases, including
impaired renal function, bleeding disorder, or any condition requiring
antibiotic pre-medication for dental visits
6 Participants with active infectious diseases such as hepatitis, HIV or
tuberculosis
7 Participants who are immunosuppressed because of medications or
condition
8 Participants who have used antibiotics or antifungals for any medical
or dental condition within 1 month prior to screening
9 Participants using ongoing medications initiated less than 3 months
prior to enrollment
10 Participants with a known or suspected intolerance to local oral
anesthesia
11 Participants who have participated in another clinical study or have
taken an investigational drug within 30 days of screening
12 Participants who have used tobacco products within 6 months of
screening
13 Employees of the sponsor or the investigator or members of their
immediate family
14 Participants who have previously participated in this study
15 Post-menopausal women on hormone replacement therapy
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Table 2
Patient demographic data
Control (n = 9)
Stomatitis (n = 10)
DS II (n = 6) DS III (n = 4) All stomatitis
Age average (SD) 71.9 (9.74) 70.3 (8.36) 64.3 (9.81) 67.9 (8.99)
Gender (M/F) 1/8 3/3 2/2 5/5
Race (Caucasian/African American/Asian) 7/2/0 5/0/1 1/2/1 6/2/2
Ethnicity (Nonhispanic/Hispanic) 9/0 6/0 4/0 10/0
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Table 4






Carbonic anhydrase 6 (CAH6) ~13 274
Cystatin C (CYTC) ~13 274
Two peptidyl-prolyl cis–trans isomerase A (PPIA) like peptides
gi|239741695 ~13267.3
gi|239741695 ~13 274
Eleven fragments of immunoglobulins (Ig) and homologous peptides
Unknown Ig-like peptide ~10 827
KV206 ~12585.1
KV206 or KV404 ~12588.8
gi|15777209 ~12607.8








The mass was IDed off the Protein Chip.
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